The Spider is Dead, Long Live the EPLA

European and US IP practitioners have eagerly awaited the Advocate General’s opinion in the Roche-Primus case. Today the AG, Philippe Léger, published his opinion in this important case (not yet available in English).

The case was referred by the Netherlands Supreme Court to the ECJ on December 19, 2003. Two years later we now have the opinion of the ECJ’s Advocate General.

The Dutch courts have long been favoured by patent owners for their willingness to provide judgments with EU cross-border effect. Plaintiffs confronted with multinational com­panies infringing their European patent could sue multiple defendants in one place – The Netherlands – to get an injunction against the defendants in each countries for which the European patent was granted.

Although the AG’s opinion is not binding on the Court, in most cases the ECJ will follow this. He summarises his conclusion as follows:


“145. Taking account of all these considerations, I therefore propose to the Court to respond to the preliminary questions referred by the Hoge Raad as follows:


Article 6(1) of the Convention of 27 September 1968 on jurisdiction and the enforcement of judgments in civil and commercial matters, as modified by the Convention of 9 October 1978 on the accession of the Kingdom of Denmark, Ireland and the United Kingdom of Great Britain and Northern Ireland, the Convention of 25 October 1982 on the accession of the Hellenic Republic, the Convention of 26 May 1989 on the accession of the Kingdom of Spain and the Portuguese Republic and the Convention of 29 November 1996 on the accession of the Republic of Austria, the Republic of Finland and the Kingdom of Sweden, should be interpreted so as not to apply in the case of proceedings for infringement of a European patent involving several companies, incorporated in different Contracting States, for acts committed on the territory of each of these States, even where these companies, belonging to the same group, acted in an identical or similar way, in accordance with a common policy conceived by one of these companies”


If the AG’s opinion is endorsed by the Court, than there is little doubt that the cross-border practice by the Dutch Courts is dead. All hopes would be then focused on the future of EPLA, the very promising initiative by some countries to come up with a workable enforcement alternative to the Community Patent, which is currently in an ailing condition too.

The AG, having summarized the most important articles of both the Brussels Convention and the European Patent Convention and their correct interpretation in § 1 – 28, the facts of the case in §§ 29 – 41, the referred questions and the scope of these questions §§ 42 – 60, the AG reaches the heart of the matter in § 61 and following.

The AG recognizes that, in protecting IP, cross-border aspects always play an important role, especially in the medical and pharmaceutical field. He touches upon the differences in enforcement of European patents under national laws and expresses hope that effective patent litigation will be conducted in several different countries (idle[?], one would think, if the ECJ follows his opinion).

The AG has several arguments in favor of a restrictive interpretation of art. 6 of the 1968 Brussels Convention.

Firstly there is the interpretation of “irreconcilable” decisions in the Kalfelis decision of the ECJ. The ECJ held In Kalfelis v.Schröder that the expression “matters relating to tort, delict or quasi-delict” has an autonomous meaning, covering all actions to seek the liability of a defendant which are not related to a “contract” within the meaning of art. 5 (1). The ECJ held that, as an exception to the general rule of art. 2, art. 5 (3) of the Brussels Convention has to be interpreted in a narrow way and that the court with jurisdiction over an action, in so far as it is based on tort, does not have jurisdiction over a non-tortious action. The Kalfelis decision established that, for art. 6 (1) to apply, there must “exist between the various actions brought by the same plaintiff against different defendants a connection of such a kind that it is expedient to determine the actions together in order to avoid the risk of irreconcilable judgments resulting from separate proceedings”.

The “connection” between the infringing acts in the Roche-Primus case was allegedly the fact that it concerned one European patent in relation to one single product which was marketed in the same or similar way by all nine Roche companies. However, AG Léger is of the opinion that the requirement of “connectivity”, introduced in Kalfelis (which went further than the text of article 6, which does not require any such “connection”) underscores the importance and “useful effect” of article 2 Brussels Convention which is the “cornerstone” of the jurisdiction arrangement of the 1968 Treaty.

Secondly, art. 22 para. 3 Brussels Convention also refers to that same “connectivity” (to prevent two similar cases against similar parties from being adjudicated by more than one court within the EU). In the so-called Tatry case, the ECJ stressed that article 21, together with article 22 on related actions, is in the interests of the proper administration of justice within the Community, to prevent parallel proceedings before the courts of different Contracting States and to avoid conflicts between decisions which might result therefrom. Those rules are meant to preclude, as much as possible, the possibility of a situation arising such as that referred to in article 27(3), that is to say the non-recognition of a judgment on account of its irreconcilability with a judgment given in a dispute between the same parties in the State in which recognition is sought. The ECJ further held in Tatry that, in light of the wording of article 21 of the Convention and the objective set out above, that article must be understood as requiring, as a condition of the obligation of the second court seized declining jurisdiction, that the parties to the two actions be identical.

The effect of a broad interpretation of article 6 means that reliance on this article becomes the exception rather than the rule. Article 22 however would have not such a consequence per se. Connected claims pending before different courts in separate jurisdictions would only result in a Judge having the discretion to refer the proceedings, rather than an obligation.

The AG is of the opinion that if one follows the Court’s approach in Kalfelis – as he suggests – article 6 would not be applicable in the absence of the necessary “connectivity” in infringement cases related to European Patents. The AG follows therefore the reasoning advocated by both Roche and the UK Government.

Dutch cross-border effect may be dead, but the need for an effective and harmonized enforcement regime in Europe is greater than ever. This latest sign that EU-wide enforcement is still a long way off, is hopefully the last and most powerful sign to the EU Commission and Member States to be more supportive in finding a way to make EPLA work. This is by far the best solution for the creation of a patent enforceable across all EU Member States.


Certainly EPLA has recieved powerful support of leading EU Patent Judges. A resolution, adopted at the Judges’ Forum held in San Servolo, Venice – October 14-16, 2005, strongly backs the EPLA initiative.

All images and illustrations used in our posts are licensed and have been legally acquired through official sources such as Adobe Stock